Vera Therapeutics (VERA) said Wednesday that it would expand the development of its lead asset, atacicept, following positive results from the ongoing phase 2 and 3 trials in patients with IgA nephropathy and other autoimmune kidney indications.
The company said it plans to initiate a study in Q4 to give its ongoing phase 2 and 3 trials participants extended access to atacicept before it becomes commercially available, allowing for the collection of longer-term data.
It added that in 2025, the company plans to launch a study to assess atacicept's efficacy and safety in expanded IgAN populations, including adults with varying levels of kidney function and adolescents at high risk of progression.
The study will also extend to autoimmune glomerular diseases like primary membranous nephropathy and focal segmental glomerulosclerosis.
Price: 44.20, Change: +1.37, Percent Change: +3.20
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。